Moderna shares are trading higher after the FDA selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program.
Portfolio Pulse from Benzinga Newsdesk
Moderna shares are trading higher after the FDA selected mRNA-3705 for the START pilot program, which supports clinical trials advancing rare disease therapeutics.
June 06, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna shares are trading higher following the FDA's selection of mRNA-3705 for the START pilot program, which aims to advance clinical trials for rare disease therapeutics.
The FDA's selection of mRNA-3705 for the START pilot program is a significant regulatory milestone for Moderna, likely to boost investor confidence and drive short-term stock price gains.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100